Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results

Bulletin Express

Aug 13

Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.

The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.

The current board comprises: • Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading • Non-executive Director – Dr. Lu An • Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai

No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1162000898"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162000898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162000898?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162000898","market":"us","top_or_hot":-1,"title":"Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results","media":"Bulletin Express","content":"<p>Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.</p>\n<p>The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.</p>\n<p>The current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai</p>\n<p>No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.</p>\n<p>The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.</p>\n<p>The current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai</p>\n<p>No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"","article_id":"1162000898","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162000898","pubTimestamp":1786621402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"Alebund Pharmaceuticals 定于 2026 年 8 月 26 日召开董事会会议批准 26 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.\nThe notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.\nThe current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai\nNo additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}